Medication Exposures and Subsequent Development of Ewing Sarcoma: A Review of FDA Adverse Event Reports

Table 3

Product labeling information on carcinogenicity for medications reported in FAERS that were used pre-ESFT diagnosis (Drugs@fda).

Black box warning:	Adalimumab, azathioprine, cyclosporine, etanercept, everolimus, infliximab, teriparatide
Warning and precautions:	Recombinant human growth hormone or somatropin, methotrexate, estrogen/medroxyprogesterone
Cancer occurrence in mice or rat studies	Isotretinoin, olanzapine, atorvastatin, methylphenidate, pregabalin, valproic acid
No increase in tumor growth rates or metastasis in mouse xenograft transplant studies	Natalizumab
No carcinogenic risk detected in long-term studies:	Clozapine
No carcinogenic risk in animal studies conducted:	Mesalamine, etonogestrel implant, xyrem
No information on carcinogenicity in labeling:	Ethosuximide
Carcinogenicity testing not adequately addressed:	Clobazam
Carcinogenicity testing not done:	Interferon beta-1a, clonazepam, peginterferon alfa-2b

http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.